Literature DB >> 19625194

Cytokine expression during chronic versus occult hepatitis B virus infection in HIV co-infected individuals.

Christina M Martin1, Jeffrey A Welge, Norah J Shire, Mohamed T Shata, Kenneth E Sherman, Jason T Blackard.   

Abstract

Chronic hepatitis B virus infection is characterized by persistent detectable levels of hepatitis B surface antigen (HBsAg) and HBV DNA in the serum. In contrast, HBsAg is not detectable during occult HBV infection, despite the presence of HBV DNA. An altered host immune response could play a role in the development of occult HBV infection; however, potential differences in immune responses among chronic and occult HBV-infected patients have not been evaluated in vivo. In the current study, we evaluated serum levels of regulatory, apoptotic, and fibrotic/anti-fibrotic cytokines/markers as indicators of immune responses in 25 chronic and 12 occult HBV-infected patients. More than half of the patients in both chronic and occult HBV infection groups had IL-2, IL-4, IL-13, and IFN-gamma levels below detectable limits. In contrast, most patients had detectable levels of IL-8, IL-10, IP-10, sFas, sFasL, and TGF-beta1. Of these, only sFas was significantly different between the two groups, with lower levels observed during occult compared to chronic HBV infection (p=0.01). As a surrogate marker of apoptotic inhibition, decreased sFas during occult HBV infection suggests that apoptosis occurs at different rates in occult compared to chronic HBV infection and therefore, may contribute to persistence of occult HBV infection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19625194      PMCID: PMC3031085          DOI: 10.1016/j.cyto.2009.06.005

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  39 in total

Review 1.  Cytokine-mediated control of viral infections.

Authors:  L G Guidotti; F V Chisari
Journal:  Virology       Date:  2000-08-01       Impact factor: 3.616

2.  Serum levels of soluble Fas antigen in chronic hepatitis C patients.

Authors:  S Iio; N Hayashi; E Mita; K Ueda; K Mochizuki; N Hiramatsu; T Kanto; Y Sasaki; A Kasahara; M Hori
Journal:  J Hepatol       Date:  1998-10       Impact factor: 25.083

3.  Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B.

Authors:  Dongping Xu; Junliang Fu; Lei Jin; Hui Zhang; Chunbao Zhou; Zhengsheng Zou; Jing-Min Zhao; Bin Zhang; Ming Shi; Xilai Ding; Zirong Tang; Yang-Xin Fu; Fu-Sheng Wang
Journal:  J Immunol       Date:  2006-07-01       Impact factor: 5.422

4.  Autocrine stimulatory mechanism by transforming growth factor beta in human hepatocellular carcinoma.

Authors:  K Matsuzaki; M Date; F Furukawa; Y Tahashi; M Matsushita; K Sakitani; N Yamashiki; T Seki; H Saito; M Nishizawa; J Fujisawa; K Inoue
Journal:  Cancer Res       Date:  2000-03-01       Impact factor: 12.701

5.  T cells with a CD4+CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection.

Authors:  Tobias Boettler; Hans Christian Spangenberg; Christoph Neumann-Haefelin; Elisabeth Panther; Simonetta Urbani; Carlo Ferrari; Hubert E Blum; Fritz von Weizsäcker; Robert Thimme
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

Review 6.  Immunology of hepatitis B infection.

Authors:  Maria-Christina Jung; Gerd R Pape
Journal:  Lancet Infect Dis       Date:  2002-01       Impact factor: 25.071

7.  Oscillating CD8(+) T cell effector functions after antigen recognition in the liver.

Authors:  Masanori Isogawa; Yoshihiro Furuichi; Francis V Chisari
Journal:  Immunity       Date:  2005-07       Impact factor: 31.745

8.  HIV-1 Tat reprograms immature dendritic cells to express chemoattractants for activated T cells and macrophages.

Authors:  Elena Izmailova; Frederic M N Bertley; Qian Huang; Norbert Makori; Christopher J Miller; Richard A Young; Anna Aldovini
Journal:  Nat Med       Date:  2003-01-21       Impact factor: 53.440

9.  Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B.

Authors:  Renate G van der Molen; Dave Sprengers; Rekha S Binda; Esther C de Jong; Hubert G M Niesters; Johannes G Kusters; Jaap Kwekkeboom; Harry L A Janssen
Journal:  Hepatology       Date:  2004-09       Impact factor: 17.425

10.  Alteration of serum cytokine balances among different phases of chronic hepatitis B virus infection.

Authors:  Minoru Ayada; Tetsuya Ishikawa; Akihiko Okumura; Junichi Tanabe; Hiroyasu Ito; Tomohiko Ohashi; Eiji Matsumoto; Ken Sato; Naoki Hotta; Yoshitaka Fukuzawa; Sinichi Kakumu
Journal:  Hepatol Res       Date:  2006-02-15       Impact factor: 4.288

View more
  14 in total

1.  Occult hepatitis B demonstrated by anti-HBc and HBV DNA in HIV-positive patients.

Authors:  Arezoo Honarmand; Morteza Pourahmad; Kavous Solhjoo; Mahmoud Kohan; Mohamad Hassan Davami; Seyed Kamyar Mostafavi Zadeh
Journal:  Rep Biochem Mol Biol       Date:  2014-10

Review 2.  Molecular mechanisms underlying occult hepatitis B virus infection.

Authors:  Jasmine Samal; Manish Kandpal; Perumal Vivekanandan
Journal:  Clin Microbiol Rev       Date:  2012-01       Impact factor: 26.132

Review 3.  Occult hepatitis B virus infection.

Authors:  Min-Sun Kwak; Yoon Jun Kim
Journal:  World J Hepatol       Date:  2014-12-27

Review 4.  Occult hepatitis B - the result of the host immune response interaction with different genomic expressions of the virus.

Authors:  George Sebastian Gherlan
Journal:  World J Clin Cases       Date:  2022-06-16       Impact factor: 1.534

Review 5.  Role of occult hepatitis B virus infection in chronic hepatitis C.

Authors:  Nicola Coppola; Lorenzo Onorato; Mariantonietta Pisaturo; Margherita Macera; Caterina Sagnelli; Salvatore Martini; Evangelista Sagnelli
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

6.  Mutations associated with occult hepatitis B in HIV-positive South Africans.

Authors:  Eleanor A Powell; Maemu P Gededzha; Michael Rentz; Nare J Rakgole; Selokela G Selabe; Tebogo A Seleise; M Jeffrey Mphahlele; Jason T Blackard
Journal:  J Med Virol       Date:  2014-08-27       Impact factor: 2.327

7.  Functional analysis of 'a' determinant mutations associated with occult HBV in HIV-positive South Africans.

Authors:  Eleanor A Powell; Ceejay L Boyce; Maemu P Gededzha; Selokela G Selabe; M Jeffrey Mphahlele; Jason T Blackard
Journal:  J Gen Virol       Date:  2016-03-31       Impact factor: 3.891

8.  HBV whole-genome mutation profile in HIV-1/HBV coinfected patients in a long-term follow-up study.

Authors:  S Taffon; D Genovese; M Blasi; P Pierotti; A Degli Esposti; S Catone; P Chionne; B Pulimanti; A Candido; S Dettori; M E Tosti; C Argentini; F Mazzotta; M Rapicetta
Journal:  Infection       Date:  2014-04-04       Impact factor: 3.553

Review 9.  Occult HBV infection.

Authors:  Giovanni Raimondo; Gaia Caccamo; Roberto Filomia; Teresa Pollicino
Journal:  Semin Immunopathol       Date:  2012-07-26       Impact factor: 9.623

Review 10.  Update on occult hepatitis B virus infection.

Authors:  Manoochehr Makvandi
Journal:  World J Gastroenterol       Date:  2016-10-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.